Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 7/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 7/20 | 0.52 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701006 | 0.83 | KCNQ3 (0.57) | MLYCDKCNQ3KCNQ2POLBHCAR2 | |
| SCHEMBL3700999 | 0.83 | KCNQ3 (0.54) | MLYCDKCNQ3KCNQ2POLBTP53 | |
| SCHEMBL3706860 | 0.80 | MAPK14 (0.56) | KCNQ3KCNQ2GAA | |
| SCHEMBL3705104 | 0.77 | KCNQ3 (0.71) | KCNQ3KCNQ2POLBGAA | |
| SCHEMBL3707305 | 0.75 | KCNQ3 (0.70) | KCNQ3KCNQ2 | |
| SCHEMBL3696279 | 0.74 | KCNQ3 (0.52) | KCNQ3KCNQ2POLB | |
| SCHEMBL3712494 | 0.73 | KCNQ3 (0.81) | KCNQ3KCNQ2 | |
| SCHEMBL3698581 | 0.73 | KCNQ3 (0.67) | KCNQ3KCNQ2GAAHCAR2 | |
| SCHEMBL3707506 | 0.72 | KCNQ3 (0.84) | KCNQ3KCNQ2 | |
| SCHEMBL3699241 | 0.71 | KCNQ3 (0.51) | KCNQ3KCNQ2POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | claimed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122888-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNJ2 | MLYCD 2640/4885KCNQ3 4/4885KCNQ2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.